These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 20841478)

  • 1. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.
    Patel KR; Brown VA; Jones DJ; Britton RG; Hemingway D; Miller AS; West KP; Booth TD; Perloff M; Crowell JA; Brenner DE; Steward WP; Gescher AJ; Brown K
    Cancer Res; 2010 Oct; 70(19):7392-9. PubMed ID: 20841478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.
    Brown VA; Patel KR; Viskaduraki M; Crowell JA; Perloff M; Booth TD; Vasilinin G; Sen A; Schinas AM; Piccirilli G; Brown K; Steward WP; Gescher AJ; Brenner DE
    Cancer Res; 2010 Nov; 70(22):9003-11. PubMed ID: 20935227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene.
    Sale S; Verschoyle RD; Boocock D; Jones DJ; Wilsher N; Ruparelia KC; Potter GA; Farmer PB; Steward WP; Gescher AJ
    Br J Cancer; 2004 Feb; 90(3):736-44. PubMed ID: 14760392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol in human cancer chemoprevention--choosing the 'right' dose.
    Scott E; Steward WP; Gescher AJ; Brown K
    Mol Nutr Food Res; 2012 Jan; 56(1):7-13. PubMed ID: 22218912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
    Garcea G; Berry DP; Jones DJ; Singh R; Dennison AR; Farmer PB; Sharma RA; Steward WP; Gescher AJ
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):120-5. PubMed ID: 15668484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
    Boocock DJ; Faust GE; Patel KR; Schinas AM; Brown VA; Ducharme MP; Booth TD; Crowell JA; Perloff M; Gescher AJ; Steward WP; Brenner DE
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1246-52. PubMed ID: 17548692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.
    Howells LM; Berry DP; Elliott PJ; Jacobson EW; Hoffmann E; Hegarty B; Brown K; Steward WP; Gescher AJ
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1419-25. PubMed ID: 21680702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence.
    Patel KR; Andreadi C; Britton RG; Horner-Glister E; Karmokar A; Sale S; Brown VA; Brenner DE; Singh R; Steward WP; Gescher AJ; Brown K
    Sci Transl Med; 2013 Oct; 5(205):205ra133. PubMed ID: 24089405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol in the management of human cancer: how strong is the clinical evidence?
    Gescher A; Steward WP; Brown K
    Ann N Y Acad Sci; 2013 Jul; 1290():12-20. PubMed ID: 23855461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of oral anthocyanins for colorectal cancer chemoprevention.
    Thomasset S; Berry DP; Cai H; West K; Marczylo TH; Marsden D; Brown K; Dennison A; Garcea G; Miller A; Hemingway D; Steward WP; Gescher AJ
    Cancer Prev Res (Phila); 2009 Jul; 2(7):625-33. PubMed ID: 19584076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could resveratrol be a useful drug for the treatment of malignant hemopathies?
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2014; 9(3):340-53. PubMed ID: 24678895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged biologically active colonic tissue levels of curcumin achieved after oral administration--a clinical pilot study including assessment of patient acceptability.
    Irving GR; Howells LM; Sale S; Kralj-Hans I; Atkin WS; Clark SK; Britton RG; Jones DJ; Scott EN; Berry DP; Hemingway D; Miller AS; Brown K; Gescher AJ; Steward WP
    Cancer Prev Res (Phila); 2013 Feb; 6(2):119-28. PubMed ID: 23233733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences.
    Hoh C; Boocock D; Marczylo T; Singh R; Berry DP; Dennison AR; Hemingway D; Miller A; West K; Euden S; Garcea G; Farmer PB; Steward WP; Gescher AJ
    Clin Cancer Res; 2006 May; 12(9):2944-50. PubMed ID: 16675592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer.
    Delmas D; Lançon A; Colin D; Jannin B; Latruffe N
    Curr Drug Targets; 2006 Apr; 7(4):423-42. PubMed ID: 16611030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of human colon cancer cells by plant compounds.
    Duessel S; Heuertz RM; Ezekiel UR
    Clin Lab Sci; 2008; 21(3):151-7. PubMed ID: 18678136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-preparative isolation of dihydroresveratrol-3-O-β-d-glucuronide and four resveratrol conjugates from human urine after oral intake of a resveratrol-containing dietary supplement.
    Radko Y; Christensen KB; Christensen LP
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 930():54-61. PubMed ID: 23727867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma.
    Burkon A; Somoza V
    Mol Nutr Food Res; 2008 May; 52(5):549-57. PubMed ID: 18435437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death.
    Aires V; Limagne E; Cotte AK; Latruffe N; Ghiringhelli F; Delmas D
    Mol Nutr Food Res; 2013 Jul; 57(7):1170-81. PubMed ID: 23495229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-estrogenic activity of a human resveratrol metabolite.
    Ruotolo R; Calani L; Fietta E; Brighenti F; Crozier A; Meda C; Maggi A; Ottonello S; Del Rio D
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1086-92. PubMed ID: 23465317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells.
    Weng YL; Liao HF; Li AF; Chang JC; Chiou RY
    Mol Nutr Food Res; 2010 Feb; 54(2):259-67. PubMed ID: 19862773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.